Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics
The promising results are part of a collaborative study between the Company and the Department of Food and Drug of the University of Parma (Italy), led and conducted by Professor Fabio Sonvico, a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company's Scientific Advisory Board.
Using a silicone-based human nasal cast and fluorescein-traced imaging, the Polyrizon hydrogel formulation was shown to exhibit a preferential accumulation of over 60% in the middle and upper turbinates, the region's most favorable for nose-to-brain transport. This region-specific delivery has the potential to be particularly promising for CNS indications, such as opioid overdose (e.g., naloxone) and benzodiazepine for epileptic seizures, where rapid and direct access to the brain can be lifesaving.
'The results validate the unique capabilities of our T&T technology in achieving localized deposition in anatomically favorable zones of the nasal cavity,' said Tomer Izraeli, CEO at Polyrizon. 'We believe that this has the potential to open a strategic path forward for leveraging our intranasal platform in the development of therapies for acute neurological and psychiatric conditions.'
Polyrizon's hydrogel demonstrated consistent, concentrated delivery to the upper nasal segments while maintaining favorable handling characteristics. These findings support the continued preclinical development of the T&T platform for CNS-targeted applications.
Polyrizon intends to further validate these results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology.
About Polyrizon
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon's proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a 'biological mask' with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief that its Trap and Target™ (T&T) platform has the potential to opens a strategic path forward for leveraging its intranasal platform in the development of therapies for acute neurological and psychiatric conditions, the continued preclinical development of the T&T platform for CNS-targeted applications and its intention to further validate these results in animal models and initiate safety studies as part of its translational roadmap for the T&T technology. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.
Contacts:
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Quantum Biopharma Ltd. (NASDAQ:QNTM) announced on Tuesday that its subsidiary Huge Biopharma Australia has received the clinical study report for a Phase 1, randomized, double-blind, placebo-controlled multiple ascending dose trial evaluating the safety and pharmacokinetics of Lucid-MS in healthy adults. The report confirms that daily dosing of Lucid-MS posed no safety or tolerability concerns, clearing a critical regulatory milestone and supporting the compound's advancement. Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis (MS).It is a patented New Chemical Entity (NCE) that has been shown in preclinical models to prevent demyelination, which is a hallmark of MS and other neurogenerative diseases and is characterized by damage to the myelin sheath surrounding nerve fibers. "The CSR allows us to advance the clinical development of Lucid-MS as it is a critical component of the investigational new drug (IND) application with the FDA," said Dr. Andrzej Chruscinski, Vice-President of Clinical and Scientific Affairs at Quantum BioPharma. "Results and observations from the first-in-human studies including this MAD investigation give us the confidence that Lucid-MS is safe and tolerable in healthy volunteers," noted Dr. Lakshmi P. Kotra, Director at Quantum BioPharma and Professor at the University of Toronto, who led the discovery of the compound. According to Benzinga Pro, QNTM stock has gained over 388% in the past year. Investors can gain exposure to the stock via AdvisorShares Psychedelics ETF (NYSE:PSIL). Price Action: At last check Tuesday, QNTM shares were trading lower by 8.63% to $25.40. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
LifeMD Reports Second Quarter 2025 Results
Total revenue increased 23% year-over-year to $62.2 million; adjusted EBITDA rose 223% to $7.1 million Telehealth revenue increased 30% to $48.6 million; telehealth adjusted EBITDA rose 560% to $3.4 million Generated more than $8 million of operating cash flow Paid down $2.1 million of senior debt, exited the quarter with $36.2 million in cash and fully repaid all remaining senior debt subsequent to quarter-end Enhanced and diversified virtual care platform with nationwide launch of behavioral health offering, upgraded LifeMD+ membership program and acquisition of women's health practice NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and six months ended June 30, 2025. Management Commentary 'The second quarter of 2025 was an extremely productive quarter for LifeMD and the evolution of our telehealth platform,' said Justin Schreiber, Chairman and CEO of LifeMD. 'Hundreds of thousands of patients now trust LifeMD to deliver affordable, accessible virtual care that meaningfully improves their health outcomes. Our platform is undergoing a transformational expansion, broadening our clinical scope into some of the most pressing and underserved areas of healthcare at a time when innovation is desperately needed. Technology-enabled virtual and in-home care platforms like ours are critical to closing this gap, and I believe we are exceptionally well positioned to transform the lives of millions of Americans in the years ahead. 'A key highlight of the second quarter was the diversification of our platform into high-need clinical areas. We launched a nationwide behavioral health offering that's unique in its ability to support both synchronous and asynchronous care, and we acquired a virtual women's health brand to accelerate our entry into this segment. In addition, we began scaling our enhanced LifeMD+ membership program, which highlights 24/7 urgent and primary care, and aggregates specialty care, prescription medications, in-home labs and wellness products and services that can help our customers manage their overall health,' Schreiber continued. 'Our long-term financial outlook remains strong and we continue to make significant strides in diversifying our offerings to optimize our position for growth and profitability,' said Marc Benathen, LifeMD's Chief Financial Officer. 'We exited the quarter with $36.2 million in cash and have now fully paid off all senior debt, significantly strengthening our balance sheet. Telehealth revenue grew 30% year-over-year and telehealth adjusted EBITDA increased 560%. WorkSimpli continued to perform well, with adjusted EBITDA increasing 119% versus the prior-year quarter. Due to some temporary challenges facing our Rex MD business—which are now largely resolved—we are revising our full-year 2025 guidance for revenue and adjusted EBITDA to reflect the full-year impact of these issues, while still anticipating strong year-over-year growth in both metrics.' Second Quarter Financial Highlights All comparisons are with the second quarter of 2024. Non-GAAP financial measures referenced below are defined and reconciled to GAAP financial measures at the end of this press release. Total revenue increased 23% to $62.2 million, driven by a 30% increase in telehealth revenue. The number of active telehealth subscribers increased 16% to approximately 297,000 at quarter-end. Gross margin was 88% compared to 90% in the prior-year period due to revenue mix. GAAP net loss was $2.9 million or ($0.06) per share compared to a net loss of $7.7 million or ($0.19) per share in the prior-year period. Adjusted EBITDA was $7.1 million compared to $2.2 million in the prior-year period. Telehealth adjusted EBITDA was $3.4 million compared to $0.5 million in the prior-year period. Cash totaled $36.2 million as of June 30, 2025 inclusive of paying down $2.1 million of senior debt during the quarter, an increase of $1.8 million from March 31, 2025. Subsequent to quarter-end, all remaining senior debt was fully repaid from existing cash. Second Quarter Key Performance Metrics ($ in 000s) Three Months Ended June 30, Y-o-Y Key Performance Metrics 2025 2024 % Growth Revenue Telehealth $ 48,564 $ 37,432 30 % WorkSimpli $ 13,655 $ 13,230 3 % Total Revenue $ 62,218 $ 50,662 23 % Active Subscribers Telehealth Active Subscribers 296,946 256,387 16 % WorkSimpli Active Subscribers 149,465 158,265 -6 % Total Active Subscribers 446,411 414,652 8 % Financial Guidance For the third quarter of 2025, the Company expects: Total revenue in the range of $61 million to $63 million, with telehealth revenue in the range of $48 million to $50 million. Adjusted EBITDA in the range of $6 million to $7 million, with telehealth adjusted EBITDA in the range of $3 million to $4 million. For the full year 2025, the Company expects: Total revenue in the range of $250 million to $255 million, compared with previous guidance of $268 million to $275 million. Telehealth revenue in the range of $195 million to $200 million, compared with $208 million to $213 million previously. Adjusted EBITDA in the range of $27 million to $29 million, compared with $31 million to $33 million previously. Telehealth adjusted EBITDA is now forecast to be in the range of $14 million to $16 million, down from $21 million previously. Conference Call LifeMD's management will host a conference call today at 4:30 p.m. Eastern time to discuss the Company's financial results and outlook, and answer questions. Details for the call are as follows: Toll-free dial-in number: 800-445-7795 International dial-in number: 785-424-1699 Conference ID: LIFEMD A live and archived webcast will be available in the Investors section of the Company's website at About LifeMD LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit Cautionary Note Regarding Forward Looking Statements This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: 'believe,' 'expect,' 'anticipate,' 'project,' 'should,' 'plan,' 'will,' 'may,' 'intend,' 'estimate,' predict,' 'continue,' and 'potential,' or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition. Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, 'Risk Factors' identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods. Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation. Investor ContactMarc Benathen, Chief Financial Officermarc@ Media ContactJessica Friedeman, Chief Marketing and Product Officerpress@ Tables to Follow LIFEMD, INC. CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 (Unaudited) ASSETS Current Assets Cash $ 36,228,305 $ 35,004,924 Accounts receivable, net 7,330,129 8,217,813 Product deposit 251,000 40,763 Inventory, net 3,251,355 2,797,358 Other current assets 1,964,974 2,672,231 Total Current Assets 49,025,763 48,733,089 Non-current Assets Equipment, net 2,050,318 1,479,184 Right of use assets 5,822,907 6,400,596 Capitalized software, net 14,837,946 13,816,501 Intangible assets, net 1,827,768 2,030,656 Total Non-current Assets 24,538,939 23,726,937 Total Assets $ 73,564,702 $ 72,460,026 LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities Accounts payable $ 24,292,870 $ 16,009,484 Accrued expenses 14,946,499 20,811,764 Current operating lease liabilities 541,981 508,537 Current portion of long-term debt 11,960,784 8,444,444 Deferred revenue 11,790,024 14,480,917 Total Current Liabilities 63,532,158 60,255,146 Long-term Liabilities Long-term debt, net 3,517,317 9,885,057 Noncurrent operating lease liabilities 6,032,847 6,265,192 Contingent consideration 100,000 100,000 Total Liabilities 73,182,322 76,505,395 Commitments and Contingencies Mezzanine Equity Preferred Stock, $0.0001 par value; 5,000,000 shares authorized Series B Convertible Preferred Stock, $0.0001 par value; 5,000 shares authorized, zero shares issued and outstanding, liquidation value, $0 per share as of June 30, 2025 and December 31, 2024 - - Stockholders' Equity (Deficit) Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately $25.55 per share as of June 30, 2025 and December 31, 2024 140 140 Common Stock, $0.01 par value; 100,000,000 shares authorized, 45,141,226 and 42,293,907 shares issued, 45,038,186 and 42,190,867 outstanding as of June 30, 2025 and December 31, 2024, respectively 451,412 422,939 Additional paid-in capital 236,426,008 230,508,339 Accumulated deficit (238,496,413 ) (236,253,218 ) Treasury stock, 103,040 shares, at cost, as of June 30, 2025 and December 31, 2024 (163,701 ) (163,701 ) Total LifeMD, Inc. Stockholders' Deficit (1,782,554 ) (5,485,501 ) Non-controlling interest 2,164,934 1,440,132 Total Stockholders' Equity (Deficit) 382,380 (4,045,369 ) Total Liabilities, Mezzanine Equity and Stockholders' Equity (Deficit) $ 73,564,702 $ 72,460,026 LIFEMD, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues Telehealth revenue, net $ 48,563,672 $ 37,432,309 $ 101,020,153 $ 68,273,711 WorkSimpli revenue, net 13,654,513 13,229,536 26,895,788 26,532,398 Total revenues, net 62,218,185 50,661,845 127,915,941 94,806,109 Cost of revenues Cost of telehealth revenue 6,838,703 4,553,843 14,975,164 8,748,438 Cost of WorkSimpli revenue 592,201 471,072 1,099,456 876,654 Total cost of revenues 7,430,904 5,024,915 16,074,620 9,625,092 Gross profit 54,787,281 45,636,930 111,841,321 85,181,017 Expenses Selling and marketing expenses 29,125,097 26,378,928 58,319,158 50,552,808 General and administrative expenses 17,565,187 18,521,385 34,620,856 33,827,117 Customer service expenses 3,230,735 2,733,418 6,302,229 4,581,459 Other operating expenses 3,028,762 1,906,175 5,543,520 4,206,622 Development costs 2,744,272 2,402,590 5,419,406 4,489,822 Total expenses 55,694,053 51,942,496 110,205,169 97,657,828 Operating (loss) income (906,772 ) (6,305,566 ) 1,636,152 (12,476,811 ) Other expenses Interest expense, net (663,027 ) (531,468 ) (1,289,302 ) (1,009,146 ) Net (loss) income before income taxes (1,569,799 ) (6,837,034 ) 346,850 (13,485,957 ) Income tax expense - - - - Net (loss) income (1,569,799 ) (6,837,034 ) 346,850 (13,485,957 ) Net income attributable to noncontrolling interests 505,075 38,606 1,036,920 158,038 Net loss attributable to LifeMD, Inc. (2,074,874 ) (6,875,640 ) (690,070 ) (13,643,995 ) Preferred stock dividends (776,562 ) (776,562 ) (1,553,125 ) (1,553,125 ) Net loss attributable to LifeMD, Inc. common stockholders $ (2,851,436 ) $ (7,652,202 ) $ (2,243,195 ) $ (15,197,120 ) Basic loss per share attributable to LifeMD, Inc. common stockholders $ (0.06 ) $ (0.19 ) $ (0.05 ) $ (0.38 ) Diluted loss per share attributable to LifeMD, Inc. common stockholders $ (0.06 ) $ (0.19 ) $ (0.05 ) $ (0.38 ) Weighted average number of common shares outstanding: Basic 44,401,531 41,296,042 43,772,151 40,269,139 Diluted 44,401,531 41,296,042 43,772,151 40,269,139 LIFEMD, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net (loss) income $ (1,569,799 ) $ (6,837,034 ) $ 346,850 $ (13,485,957 ) Adjustments to reconcile net (loss) income to net cash provided by operating activities: Amortization of debt discount 100,444 100,444 200,888 200,888 Amortization of capitalized software 2,377,484 1,937,708 4,627,520 3,725,112 Amortization of intangibles 261,360 246,066 505,888 492,032 Accretion of consideration payable - - - 13,644 Depreciation of fixed assets 184,256 104,451 346,822 170,366 Noncash operating lease expense 281,956 184,588 577,689 391,397 Stock compensation expense 2,094,614 4,191,176 4,643,142 6,735,606 Changes in Assets and Liabilities Accounts receivable 2,862,645 (331,451 ) 887,684 (390,692 ) Product deposit (59,160 ) 172,804 (210,237 ) 369,716 Inventory (283,658 ) 312,921 (453,997 ) 699,213 Other current assets 262,226 (222,683 ) 707,257 (586,910 ) Operating lease liabilities (94,004 ) (130,846 ) (198,901 ) (334,790 ) Deferred revenue (2,835,878 ) 1,958,902 (2,690,893 ) 6,333,061 Accounts payable 8,613,842 2,656,697 8,283,386 3,966,874 Accrued expenses (3,556,881 ) 196,020 (5,865,264 ) 1,442,362 Net cash provided by operating activities 8,639,447 4,539,763 11,707,834 9,741,922 CASH FLOWS FROM INVESTING ACTIVITIES Cash paid for capitalized software costs (2,903,838 ) (2,488,039 ) (5,648,965 ) (4,502,712 ) Purchase of equipment (795,745 ) (642,053 ) (917,956 ) (817,645 ) Purchase of intangible assets - (1,936 ) - (1,936 ) Net cash used in investing activities (3,699,583 ) (3,132,028 ) (6,566,921 ) (5,322,293 ) CASH FLOWS FROM FINANCING ACTIVITIES Repayment of notes payable, net of prepayment penalty - (102,887 ) - (314,577 ) Repayment of debt instruments (2,052,288 ) - (2,052,288 ) - Cash proceeds from exercise of options - 100,000 - 107,813 Preferred stock dividends (776,562 ) (776,562 ) (1,553,125 ) (1,553,125 ) Contingent consideration payment for ResumeBuild - - - (31,250 ) Distributions to non-controlling interest (276,119 ) (36,000 ) (312,119 ) (72,000 ) Net cah used in financing activities (3,104,969 ) (815,449 ) (3,917,532 ) (1,863,139 ) Net increase in cash 1,834,895 592,286 1,223,381 2,556,490 Cash at beginning of period 34,393,410 35,110,929 35,004,924 33,146,725 Cash at end of period $ 36,228,305 $ 35,703,215 $ 36,228,305 $ 35,703,215 Cash paid for interest Cash paid during the period for interest $ 625,818 $ 637,788 $ 1,219,568 $ 1,282,707 Non-cash investing and financing activities: Cashless exercise of options $ 501 $ 4,489 $ 1,062 $ 5,127 Cashless exercise of warrants $ 3,901 $ 3,620 $ 3,901 $ 16,305 Stock issued for debt conversion $ 1,000,000 $ - $ 1,000,000 $ - Stock issued for asset acquisition $ 303,000 $ - $ 303,000 $ - Stock issued for noncontingent consideration payments $ - $ - $ - $ 642,000 Right of use asset $ - $ 1,045,305 $ - $ 2,331,231 Operating lease liabilities $ - $ 1,045,305 $ - $ 2,331,231 About the Use of Non-GAAP Financial Measures:To supplement our financial information presented in accordance with GAAP, we use adjusted EBITDA as a non-GAAP financial measure to clarify and enhance an understanding of past performance. Additionally, we report telehealth adjusted EBITDA as a non-GAAP financial measure to clarify the financial performance of our core telehealth business excluding WorkSimpli. We believe that the presentation of these financial measures enhances an investor's understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. Adjusted EBITDA is defined as income (loss) attributable to common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, non-controlling interests, foreign currency translation, extraordinary litigation costs, loss on debt extinguishment, dividends, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of adjusted EBITDA to net loss attributable to common shareholders, its most directly comparable GAAP financial measure. Telehealth and WorkSimpli adjusted EBITDA is defined as segment operating income or loss before depreciation, amortization, accretion, financing transaction expense, extraordinary litigation costs, insurance acceptance and Sarbanes-Oxley readiness expenses, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of segment operating income or loss to segment Adjusted EBITDA. We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted EBITDA may vary from that of others in our industry. Telehealth adjusted EBITDA is specifically relevant to LifeMD to provide shareholders a comparable measure of profitability for our core telehealth business without the impact of our majority owned, but separately managed non-core subsidiary, WorkSimpli. Adjusted EBITDA, telehealth adjusted EBITDA and WorkSimpli adjusted EBITDA should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance. Reconciliation of Consolidated GAAP Net Loss to Consolidated Adjusted EBITDA (in whole numbers, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Net loss attributable to common shareholders $ (2,851,436 ) $ (7,652,202 ) $ (2,243,195 ) $ (15,197,120 ) Interest expense (excluding amortization of debt discount) 562,583 431,024 1,088,414 808,258 Depreciation, amortization and accretion expense 2,823,100 2,288,225 5,480,230 4,401,154 Amortization of debt discount 100,444 100,444 200,888 200,888 Financing transactions expense - 151,143 - 323,372 Litigation costs (a) 486,462 495,784 739,659 678,331 Severance costs 25,535 360,182 102,417 520,677 Acquisitions expenses 1,806,277 - 2,014,777 - Insurance acceptance readiness 34,780 263,492 175,140 969,834 Sarbanes Oxley readiness - 23,220 - 183,128 Foreign exchange loss 253,512 504,969 485,159 478,721 Taxes 502,408 3,000 502,408 3,000 Dividends 776,562 1,004,793 1,553,125 2,048,173 Stock-based compensation expense 2,094,614 4,191,176 4,643,142 6,735,606 Net income attributable to noncontrolling interests 505,075 38,606 1,036,920 158,038 Consolidated Adjusted EBITDA $ 7,119,915 $ 2,203,856 $ 15,779,084 $ 2,312,060 Reconciliation of Telehealth GAAP Operating Loss to Telehealth Adjusted EBITDA (in whole numbers, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Telehealth operating loss $ (2,802,097 ) $ (6,450,683 ) $ (2,415,231 ) $ (13,070,446 ) Depreciation, amortization and accretion expense 1,785,344 1,485,696 3,476,753 2,848,770 Financing transactions expense - 151,143 - 323,372 Litigation costs (a) 486,462 495,784 739,659 678,331 Severance costs 25,535 360,182 102,417 520,677 Acquisitions expenses 1,806,277 - 2,014,777 - Insurance acceptance readiness 34,780 263,492 175,140 969,834 Sarbanes Oxley readiness - 23,220 - 183,128 Stock-based compensation expense 2,094,614 4,191,176 4,643,142 6,735,606 Telehealth Adjusted EBITDA $ 3,430,914 $ 520,010 $ 8,736,657 $ (810,728 ) (a) For the three and six months ended June 30, 2025 and June 30, 2024, the Company included costs related to a class action complaint alleging, inter alia, unauthorized disclosure of certain information of class members to third parties (the Marden v. LifeMD, Inc. case), as disclosed in the Company's Form 10-Q for the three and six months ended June 30, 2025, filed on August 5, 2025, and a heavily negotiated executive separation agreement. Reconciliation of WorkSimpli GAAP Operating Income to WorkSimpli Adjusted EBITDA (in whole numbers, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 WorkSimpli operating income $ 1,895,325 $ 145,116 $ 4,051,383 $ 593,635 Depreciation, amortization and accretion expense 1,037,756 802,529 2,003,477 1,552,384 Foreign exchange loss 253,512 504,969 485,159 478,721 Distributions - 228,231 - 495,048 Taxes 502,408 3,000 502,408 3,000 WorkSimpli Adjusted EBITDA $ 3,689,001 $ 1,683,845 $ 7,042,427 $ 3,122,788
Business Wire
3 hours ago
- Business Wire
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45 th Annual Growth Conference
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Canaccord Genuity 45 th Annual Growth Conference on Wednesday, August 13, 2025 at 2:30 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neurological and rare diseases to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X.
